Abstract
The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.
Keywords: Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.
Current Cancer Therapy Reviews
Title:Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer
Volume: 10 Issue: 1
Author(s): Paul Brittain, S. Gail Eckhardt and Christopher H. Lieu
Affiliation:
Keywords: Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.
Abstract: The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including potential rational combination strategies and the investigation into potential predictive biomarkers of response.
Export Options
About this article
Cite this article as:
Brittain Paul, Eckhardt Gail S. and Lieu H. Christopher, Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152055
DOI https://dx.doi.org/10.2174/157339471001140815152055 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Functional Peptides from Natural and Synthetic Products on Their Anticancer Activities by Tumor Targeting
Current Medicinal Chemistry Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Current Drug Targets C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Recent Patents and Advances in Genomic Biomarker Discovery for Colorectal Cancers
Recent Patents on DNA & Gene Sequences Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Patent Selections:
Recent Patents on Regenerative Medicine Genistein: A Boon for Mitigating Ischemic Stroke
Current Topics in Medicinal Chemistry Assembly of Quinoline, Triazole and Oxime Ether in a Single Molecular Entity: A Greener and One-pot Synthesis of Novel Oximes as Potential Cytotoxic Agents
Letters in Drug Design & Discovery Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry The Role of MRI in Treatment Planning for Rectal Cancer - A Review
Current Cancer Therapy Reviews Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals
Current Pharmaceutical Design Chemopreventive Effects of Conjugated Linolenic Acids (CLN) Occurring in Plant Seed Oils
Current Nutrition & Food Science Evaluating the Susceptibility of Mitochondrial DNA Germline Mutations in Chinese Cancer Patients
Current Molecular Medicine Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets